Fig. 1From: Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort studyDescription of FIRST registry. Number of registered patients and distribution of biological disease-modifying anti-rheumatic drug (bDMARD) users by drug types in each year is shown. IFX, infliximab; ETN, etanercept; TCZ, tocilizumab; ADA, adalimumab; ABT, abatacept; GLM, golimumab; CZP, certolizumab; Tofa, tofacitinibBack to article page